A method implemented by one or more computer device includes accessing a set of medical data associated with a patient, in which the set of medical data includes a plurality of modalities of medical data. The method includes inputting one or more one of the plurality of modalities of medical data into a first machine-learning model trained to generate a first vector representation and inputting another one of the plurality of modalities of medical data into a second machine-learning model trained to generate a second vector representation. The method includes generating a combined vector representation based on the first vector representation and the second vector representation,and storing the combined vector representation to a database associated with the one or more computing devices.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
2.
DETERMINING A PATIENT'S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA
The present disclosure relates to a computer-implemented method of a computer- implemented method of determining a patient's response to a treatment in multiple myeloma. The method comprises: providing results of a series of predefined consecutive tests on the patient, determining a response at time t as a function of a test result of the time t and a subsequent test result of a time t +1.
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
The present invention relates to an infusion delivery device comprising a reservoir that is configured for containing a liquid medicament, a dispensing member that is moveably arranged within the reservoir for dispensing liquid medicament out of the reservoir through an outlet of the reservoir, an actuation member that is configured for moving the dispensing member within the reservoir, and a controller that is configured for controlling the movement of the dispensing member within the reservoir by the actuation member, wherein the controller is further configured to determine an occlusion hindering the dispensing of liquid medicament out of the reservoir and that is configured to provide a control signal to the actuation member, upon determining an occlusion, to move the dispensing member in a reverse direction about a displacement distance. In order to prevent an overdosing or underdosing in case of an occlusion, the displacement distance is a model-based displacement distance.
The present invention relates to a method for the identification of compounds modulating the protein-protein interaction between a protein comprising a NTF2-like domain of G3BP2 having the amino acid sequence set forth in Seq. Id. No. 3 and Tau protein, for the treatment of a Tau associated diseases.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
5.
TROPONIN MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10- type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
The present application discloses combinations for treating estrogen receptor-positive and HER2-positive breast cancer patients. The combinations comprise pertuzumab and trastuzumab (e.g. a fixed dose combination of pertuzumab and trastuzumab, PH FDC) plus giredestrant. In one embodiment, the combination further includes a CDK4/6 inhibitor, such as abemaciclib or palbociclib.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to a compound of formula (I) wherein R1-R3122 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
A61P 25/00 - Drugs for disorders of the nervous system
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 207/10 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 223/06 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 265/30 - 1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
10.
BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
The present invention relates to compounds of formula (I), wherein R1to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to an analyte sensor (100) for use in medical devices for measuring analyte data, in particular for measuring glucose data, comprising: a power source (102) for providing electrical power to the analyte sensor (100), an enclosure (101) of the analyte sensor, a sensor circuit (103) powered by said power source and comprising two electrodes (105, 106), wherein said electrodes (105, 106) each have a first portion (105a, 106a) that lies inside the enclosure (101) and a second portion (105b, 105b) that lies outside of the enclosure (101), at least one protection unit (107), wherein said protection unit (107) is electrically coupled to the first portion (105a, 106a) of each of the two electrodes (105, 106) that is located inside the enclosure (101), and wherein said at least one protection unit (107) is configured to short-circuit the two electrodes (105, 106) in case a voltage signal from the sensor circuit (103) applied to the electrodes (105, 106) exceeds a predetermined voltage threshold. The invention further relates to a method (300) for operating an analyte sensor.
The present invention includes: a reagent vessel holding part that holds a reagent vessel for accommodating a reagent; a reagent vessel information detection unit that detects information relating to the reagent vessel; a display unit that displays a screen including an operation region where operations from a user are received; and a control unit that causes the display unit to display the screen. The control unit has: a vessel presence/absence determination unit that determines whether the reagent vessel is present in the reagent vessel holding unit on the basis of the information detected by the reagent vessel information detection unit; a first operation region output unit that outputs, to the screen, a first operation region which is operated when the user has confirmed removal of the reagent vessel; a second operation region output unit that outputs, to the screen, a second operation region which is operated when shutdown is performed; and a warning output unit that outputs, to the screen, a warning prompting removal of the reagent vessel when the vessel presence/absence determination unit has determined that the reagent vessel is present. The foregoing makes it possible to provide an automated analysis device which prevents shutdown from starting while a reagent has been left behind.
The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12and R13 are as described herein (I). Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided are phenyltetrahydrofuran compounds that are useful as intermediates in the preparation of pharmaceutical compounds and further provided are processes for the preparation of phenyltetrahydrofuran compounds.
The present invention relates to a method for determining at least one analyte of interest and the use thereof. The present invention further relates to a kit, a complex, a method to synthesize a complex, a monomer and the use thereof for detecting the analyte of interest in the sample.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being DLL1, determining the amount of a second biomarker in a sample of the subject, said second biomarker being GDF15, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being DLL1 and a second biomarker being GDF15, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50 % of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
The present invention relates to antisense oligonucleotides that reduce expression of A1CF, as well as conjugates, salts and pharmaceutical compositions thereof. The invention also relates to uses of such antisense oligonucleotides, conjugates, salts and pharmaceutical compositions in methods for reducing A1CF expression and in medical uses and methods of treatment of disease, particularly treatment of hepatitis B virus (HBV) infection.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The invention provides new bicyclopentanyl compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, and R5 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
A61P 25/00 - Drugs for disorders of the nervous system
The present invention relates to systems and methods to detect liver cirrhosis in digital images. Various embodiments of the present invention relate to systems and methods to detect liver cirrhosis in computed tomography (CT) scans and, more specifically but not limited, to systems and methods to detect liver cirrhosis via a model trained on highly-interpretable features.
The invention relates to a body-wearable medical device with a medical device housing comprising a transcutaneous element that is configured for being at least partially inserted into a patient's body at an insertion site during use of the body-wearable medical device, and a base portion that is configured for reversibly attaching the body-wearable medical device during its use to a patient's skin, wherein the base portion comprises a first side that during use of the body-wearable medical device faces the patient's body and that comprises an adhesive for adhering the body-wearable medical device to a patient's skin. For reducing a likelihood of a contamination by bodily fluid flowing out of the insertion lesion, the base portion on its first side further comprises a superabsorbent substance and at least one fluid channel, the at least one fluid channel being configured to guide bodily fluid from the insertion site to the superabsorbent substance.
The present invention relates to a body-wearable medical device comprising a first housing portion and a second housing portion, the first housing portion having a female portion and the second housing portion having a male portion, the male portion is at least partially inserted into the female portion thereby defining a circumferential clearance gap, wherein a circumferential sealing element is arranged in the circumferential clearance gap between the female portion and the male portion. In order to provide a body-wearable medical device comprising an improved sealing that is less prone to failure by stress and forces exerting on the body-wearable medical device, the female portion and the male portion are fixed to each other by a circumferential fixation glue that is arranged in the circumferential clearance gap between the female portion and the male portion next to the circumferential sealing element.
Methods and devices for determining the concentration of at least one analyte in a bodily fluid A determination method of determining a color expectation range (132) for assessing the plausibility of a color formation value obtained in an analytical measurement based on a color formation reaction and a measurement method of performing an analytical measurement based on a color formation reaction by using a mobile device (112) having a camera (114) and a processor (130) are disclosed. Further disclosed are a determination system (110) for determining a color expectation range (132) for assessing the plausibility of a color formation value obtained in an analytical measurement based on a color formation reaction. The determination system comprises a training set of optical test strips (116) having a reagent test region (120). At least two of the training optical test strips are non-corrupted (122) and at least two are corrupted (124).
Provided is a component abnormality detecting system for detecting an abnormality of a component of a liquid transport system that sucks in and discharges a liquid to and from a sample inspection sensor of an automated analyzing device, the component abnormality detecting system comprising a storage device for storing data of an electrical signal output by the sensor, and a processing device for processing the data recorded in the storage device, wherein the processing device detects an abnormality of a component of the liquid transport system on the basis of the electrical signal.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
26.
METHODS AND DEVICES FOR DETERMINING THE CONCENTRATION OF AT LEAST ONE ANALYTE IN A BODILY FLUID
A determination method of determining at least one color expectation range (128) for assessing the plausibility of an assumed reaction time value used in an analytical measurement based on a color formation reaction and a measurement method of performing an analytical measurement based on a color formation reaction by using a mobile device (112) having a camera (114) and a processor (126) are disclosed. Further disclosed are a determination system (110) for determining at least one color expectation range (128) for assessing the plausibility of an assumed reaction time value used in an analytical measurement based on a color formation reaction, a mobile device (112) having at least one camera (114) and at least one processor (130), a kit (134) for determining the concentration of at least one analyte in a sample of a bodily fluid (128) comprising said mobile device (112) as well as computer programs and computer-readable storage media comprising instructions which, when performed on the respective device cause the device to perform the determination method and/or the measurement method.
G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 21/84 - Systems specially adapted for particular applications
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 21/75 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
27.
METHODS AND DEVICES FOR PERFORMING AN ANALYTICAL MEASUREMENT
vTR, limvTRvRF, minvTR, limvRF, minvTR, limvTR, maxvTR, max) for reagent test regions (114) of non-corrupted optical test strips (116). Further, a measurement method of performing an analytical measurement based on a color formation reaction by using a mobile device (122) having a camera (124) and a processor (138), a determination system (110), a mobile device (122), computer programs and computer-readable storage media are disclosed.
The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof, wherein PG1, PG2and PG3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 5/04 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
29.
ELECTRONIC CIRCUIT AND ANALYTE SENSOR SYSTEM SUCH AS A GLUCOSE SENSOR SYSTEM AND METHOD OF OPERATING AN ANALYTE SENSOR AND SYSTEM
The invention refers to an electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively, wherein the electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein with the voltage source an electric potential different to the potential of the common potential conductor section can be provided to the first electrical connection; and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths and wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.
The present invention relates to compounds of formula (Ia), (Ia), wherein R2, M1, M2, M3, Q1and Q2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/529 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided herein are methods to synthesize compounds useful in the treatment of cancer where such compounds comprise a quinazolinyl core moiety and at least one stereoisomeric or atropisomeric moiety.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
pRR0000p0000p0iiiii, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
34.
METHOD FOR OPERATING LABORATORY SYSTEM AND LABORATORY SYSTEM
A method for operating a laboratory system is disclosed, comprising providing a laboratory system having a plurality of sample containers (1) configured to contain a sample to be processed for at least one of pre-analysis and analysis in the laboratory system; a plurality of laboratory devices (2; 3; 4; 6) providing for a plurality of target devices each configured to handle one or more sample containers from the plurality of sample containers (1), the one or more sample containers being assigned for handling to the target device in operation of the laboratory system; and a control device (5) configured to at least control assignment of the plurality of sample containers (1) to the plurality of target devices; and assigning the plurality of sample containers (1) to the plurality of target devices in operation of the laboratory system. The assigning comprises: determining a target device workload state for each of the plurality of target devices, the target device workload state being in a range between a first range limit indicative of a first capacity for handling sample containers and a second range limit indicative a second capacity for handling sample containers, the second capacity being a higher capacity than the first capacity for handling sample containers, and determined according to a metric being proportional to a resource target device state indicative of a present number of sample containers assigned to the target device, and a power of an output flow of the target device, the output flow being indicative of output of sample containers per time by the target device; assigning the plurality of sample containers (1) to the plurality of target devices according to the target device workload states; and providing the plurality of sample containers (1) to the plurality of target devices for handling according to the assignment. Furthermore, a laboratory system is provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G05B 19/042 - Programme control other than numerical control, i.e. in sequence controllers or logic controllers using digital processors
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control (DNC), flexible manufacturing systems (FMS), integrated manufacturing systems (IMS), computer integrated manufacturing (CIM)
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
36.
TREATMENT OF AUTOIMMUNE ENCEPHALITIS WITH SATRALIZUMAB
All currently available treatment options for autoimmune encephalitis such as anti-NMDAR encephalitis and anti-LGI1 encephalitis carry substantial potential safety risks. Further, no approved therapies exist for anti-NMDAR encephalitis and anti-LGI1 encephalitis. The invention provides a means for a treatment for autoimmune encephalitis (AIE) such as NMDAR encephalitis and anti-LGI1 encephalitis, comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof.
The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
38.
A COMPOSITION FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST VIA MASS SPECTROMETRY MEASUREMENTS
The present invention relates to a composition for determining at least one analyte of interest via Mass Spectrometry measurements and uses thereof, a kit and the use thereof, a method of determining the level of at least one analyte of interest in an obtained sample, a sampling tube for collecting a patient sample, an analyzer as well as the use of dialkyl sulfide as an additive in a formulation of β-lactam antibiotic analyte for preventing oxidation.
The present invention relates to a method of determining the level of at least one analyte of interest, sampling tubes for collecting a patient sample, the use of nucleophilic derivatization reagents, an analyzer as well as kits.
The present invention relates to a method of predicting an off-target event of CRISPR-Cas system comprising a guide RNA to be tested and Cas protein, comprising identifying more than one potential targeting sequences for a guide RNA to be tested, optionally, identifying all the potential targeting sequences across the genome for the guide RNA to be tested; determining a cleavage probability for each hybrid between the guide RNA to be tested and any one of the one or more potential targeting sequences based on one or more secondary features, particularly more than one secondary features for a nucleotide pair of a hybrid between the guide RNA to be tested and the potential targeting sequence; determining a cleavage specificity of the guide RNA to be tested based on the cleavage probability for each hybrid between the guide RNA to be tested and any one of the one or more potential targeting sequences.
The present invention relates to a computer-implemented method, a mobile device, and a computer program, for managing medical data such as, e.g., a glucose concentrations, by an electronic disease management system comprising detecting a change of the local time between generation of a first set of medical data and a second set of medical data.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G01N 33/487 - Physical analysis of biological material of liquid biological material
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
42.
AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM
The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The invention relates to a laboratory apparatus (1), wherein the laboratory apparatus (1) comprises, - a housing (2), wherein the housing (2) comprises a through-opening (3), wherein the through-opening (3) is adapted for passing through it a transport device (4) for transporting laboratory sample containers (5) in and/or out of the housing (2), and - a cover (6), wherein the cover (6) comprises at least two ring segments (7a, 7b), wherein the ring segments (7a, 7b) are adjustable to each other between a distant adjustment (da) with at least one distance (Dla, Dlb) in between ends (7aE, 7bE) of the ring segments (7a, 7b) for arranging them around the passed through transport device (4) and a near adjustment (na) with less or no distance in between the ends (7aE, 7bE) of the ring segments (7a, 7b) for surrounding the passed through transport device (4), and wherein the cover (6) in the near adjustment (na) is adapted to cover a part (3f) of the through-opening (3) left free by the passed through transport device (4), - wherein the laboratory apparatus (1) is a pre-analytical, analytical, and/or post-analytical laboratory apparatus (1'), in particular a sorting module (1").
The present invention relates to antisense oligonucleotide splice modulators Unc-13 homolog A (UNC13A). These antisense oligonucleotide splice modulators are complementary, such as fully complementary, to the UNC13A precursor-mRNA, and are capable of increasing or restoring expression of UNC13A in TDP-43 depleted cells, such as for use in conditions and medical indications where TDP-43 is functionally depleted.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to methods to improve detection of amplification products from Loop-mediated Amplification (LAMP) reactions by the use of nucleotide analogs that form duplex structures that nucleic acid polymerase enzymes do not recognize efficiently.
Methods of extracting information about protein sequence modifications in a protein are disclosed. Protein data derived from mass spectrometry measurements performed on peptides from at least two enzymatic digests is received. Candidate sequence modifications are identified. A subset of the candidate sequence modifications that have a higher average probability of representing true sequence modifications than the rest of the candidate sequence modifications are determined. The determination of the subset of candidate sequence modifications comprises a step of selecting candidate sequence modifications dependent on the candidate sequence modifications being at amino acid sequence positions that are covered by at least two different peptide species that each contain the modification.
A computer-implemented method of differentiating between lymphoid blast cells and myeloid blast cells comprises: receiving (S30) a digital image containing one or more blast cells; applying (S34) a parametric model classifier (412) to one or more portions of the digital image each containing a respective blast cell, the parametric model (416) configured to generate an output (S38) indicative of whether each blast cell is a lymphoid blast cell or a myeloid blast cell. Computer- implemented methods of training a parametric model (416) are also provided, as well as a clinical decision support system (400) relying on the computer-implemented method of classifying blast cells.
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
48.
TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
49.
METHOD FOR THE DETERMINATION OF HYDROLYTIC ACTIVITY
Herein is reported a method for determining the presence of hydrolase activity in a sample by incubating the sample in a buffered solution, which comprises an artificial hydrolase substrate that comprises an ester bond covalently linking an alcohol residue, which is conjugated to a label for removal, and a carboxylic acid residue, 5 which is conjugated to a capture and detection label, as well as bovine serum albumin, and thereafter determining or quantifying, respectively, the released carboxylic acid in the free alcohol depleted incubation mixture.
Described are antisense oligonucleotides comprising one or more α-L-threofuranosyl (TNA) nucleosides as well as methods to modulate the properties of antisense oligonucleotides by the introduction of TNA nucleosides. These are particularly applicable for antisense gapmer oligonucleotides.
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
The present invention provides analyte sensor system which comprises a body wearable analyte sensor device, comprising a transcutaneous analyte sensor, a housing comprising a lower side which can be attached to the skin of a patient, a IR temperature sensor which is configured to detect the temperature of the lower side of the housing or to detect the temperature of the skin, and wherein the IR temperature sensor faces without contact the lower side of the housing, and a processor configured to receive signals from the analyte sensor and from the IR temperature sensor. In addition, a method of determing an analyte concentration using an analyte sensor system (1) of the invention is provided.
A method of determining the concentration of at least one analyte in a sample (112) is proposed. The method comprises: i. providing at least one sensor device (110), the sensor device (110) comprising - at least one field effect transistor (114) having at least one source electrode (116), at least one drain electrode (118) and at least one gate electrode (120), • - at least one sensing electrode (132) configured for being in contact with the sample (112), the sensing electrode (132) being at least one of electrically connected to the gate electrode (120) of the field effect transistor (114) or integrated into the gate electrode (120) of the field effect transistor (114), and • - at least one control device (146), the control device (146) being configured for applying operation parameters to the field effect transistor (114) and for monitoring at least one signal value with the field effect transistor (114); • ii. at least one parameter selection step comprising selecting a set of operation parameters of the field effect transistor (114) for at least one subsequent measurement step, the parameter selection step comprising performing a plurality of evaluation measurements with the field effect transistor (114) by using various sets of operation parameter candidates and by selecting the set of operation parameters in accordance with at least one optimization criterion monitored during the evaluation measurements; and • iii. at least one measurement step comprising detecting the concentration of the analyte by applying the set of operation parameters selected in step ii. to the field effect transistor (114) and by determining at least one signal value with the field effect transistor (114). Further, a sensor device (110) for determining the concentration of at least one analyte in a sample (112) is proposed.
Kutzneria albidaKutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within the antibody's heavy chain and/or light chain. The invention further relates to one or more nucleic acids encoding the modified antibody according to the invention as well as a covalent conjugate comprising (i) the modified antibody according to the invention and (ii) one or more non-antibody moieties (payload(s)) covalently conjugated to the one or more first recognition site(s) either directly or via a first linker. In certain embodiments, the non-antibody moiety comprises a therapeutic entity and optionally a second linker. The present invention further relates to a method of covalently conjugating a modified antibody according to the invention to non-antibody moieties. In case the non-antibody moiety comprises a therapeutic entity, the present invention further relates to the conjugate of the modified antibody according to the invention and the therapeutic entity as pharmaceutical composition, for use as a medicament as well as for use in treating a disease.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
55.
METHODS FOR CLUSTERING MELTING CURVES TO IDENTIFY GENOTYPES
Automated methods for genotyping melting curves are described. Melting curves are processed and difference matrices are compiled based on the processed matrices. The difference matrices are used to compile a cluster matrix and the cluster matrix is filtered to determine clusters that are used for genotyping the melting curves.
The invention provides new heterocyclic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, R5, R6, R7and R8 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to a laboratory sample container carrier handling apparatus (1) comprising a revolving device (2) and a guiding surface (S), wherein an entry segment (EP) of the guiding surface (S) is adapted to smoothly receive a laboratory sample container carrier (3). The invention further relates to a laboratory automation system (100) comprising such a laboratory sample container carrier handling apparatus (1) and to a use of such a laboratory sample container carrier handling apparatus (1) for handling a laboratory sample container carrier (3) in, in particular such, a laboratory automation system (100).
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
58.
ANTIBODIES AGAINST COAGULATION FACTOR X AND USES THEREOF
The present invention refers to antibodies that specifically bind coagulation Factor X (FX), or fragments thereof, inhibit its enzymatic activity and can deplete it from human blood-derived samples. The present invention also refers to compositions and kits comprising said antibodies and to methods for detecting, inhibiting and/or depleting FX from samples with said antibodies, compositions or kits or uses thereof. The present invention also refers to compositions generated from blood-derived samples by depleting and/or inhibiting FX, or fragments thereof, and their uses as abnormal coagulation controls in in vitro assays.
An adapter (1) for connecting a dispenser to a container having a neck with an interior passage comprises a body portion (2) with a container end (27) and a dispenser end (23, 25) opposite to the container end (27). The body portion (2) has a longitudinal axis (21) centrally extending between the dispenser end (23, 25) and the container end (27), and an essentially cylindrical outer surface (22). The body portion (2) comprises sealing lamellas (24) outwardly extending from the outer surface (22). The sealing lamellas (24) of the body portion (2) are spaced from each other along the longitudinal axis (21). Each of the sealing lamellas (24) of the body portion (2) has a root end adjoining the outer surface (22) of the body portion (2). The root ends of at least two neighboring sealing lamellas (24) have different thicknesses.
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 with advantageous features for Aß42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 as provided herein.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to oligonucleotides that upregulate or restore the expression of glucocerebrosidase (GBA) in cells; conjugates, salts and pharmaceutical compositions thereof; and methods for treatment of diseases associated with reduced expression of GBA, including Gaucher's disease and/or Parkinson's disease.
A method and system for predicting a selected treatment regimen for a subject. Baseline data for a subject diagnosed with neovascular age-related macular degeneration (nAMD) is received. A plurality of predictor inputs is formed for an outcome predictor using the baseline data and regimen data for a plurality of treatment regimens. The plurality of predictor inputs comprises a different predictor input for each of the plurality of treatment regimens. A plurality of treatment scores is generated for the plurality of treatment regimens via the set of outcome predictor using the plurality of predictor inputs. One of the plurality of treatment regimens is selected as a selected treatment regimen for the subject based on the plurality of treatment scores.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
63.
DETECTING OCULAR COMORBIDITIES WHEN SCREENING FOR DIABETIC RETINOPATHY (DR) USING 7-FIELD COLOR FUNDUS PHOTOS
A method and system for detecting a presence of comorbid ocular conditions. Input data that includes imaging data for an eye of a subject is received. A score that indicates whether a presence of a plurality of comorbid ocular conditions is detected is generated in the eye of the subject using a deep learning model and the input data. A comorbidity output is generated based on the score. The comorbidity score may be a classification indicating whether the presence of the plurality of comorbid ocular conditions is detected.
The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/MAGE-A4 x CD3 bispecific antibody and a 4-1BB (CD137) agonist.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
65.
METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL
A method for characterization of a mass spectrometry instrument (100) comprising at least one mass analyzing cell (102, 104, 106) is proposed. The method comprising the steps of analyzing a sample (110) comprising at least one substance having a known molecular weight by means of the mass spectrometry instrument (100) so as to provide a mass spectrum (116, 118, 144, 146) of the sample (110), determining an outer envelope and an inner envelope of the mass spectrum (116, 118, 144, 146), calculating a squared difference between the outer envelope and the inner envelope, and determining a deviation of the calculated squared difference from a theoretical mass to charge ratio value of the substance.
The invention provides new MAGL inhibitors having the general formula (II)AB(II)wherein the variables are as described herein, compositions including the compounds,processes of manufacturing the compounds and methods of using the compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
67.
COMPUTER-IMPLEMENTED METHOD FOR PERFORMING A CLINICAL PREDICTION
A computer-implemented method for performing a clinical prediction is disclosed. The method comprises the following steps: i) (110) retrieving input data via at least one communication interface (164) of a processing device (166), wherein the input data comprises multiple different modalities of a patient; ii) (114) processing the input data by using the processing device (166), wherein the processing comprises generating embedding modality representations from the input data by using at least one trainable data embedder, wherein the processing comprises combining the embedding modality representations using at least one aggregation network thereby generating the clinical prediction, wherein the aggregation network comprises at least one attention layer and/or at least one transformer layer; and iii) (118) generating an output of the clinical prediction by using the processing device (166).
G06N 3/04 - Architecture, e.g. interconnection topology
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
The present invention relates to combinations of Regulator of telomere elongation helicase 1 (RTEL1) and Far Upstream Element-Binding Protein 1 (FUBP1) inhibitors, such as oligonucleotides (oligomers) that are complementary to RTEL1 or FUBP1, respectively, leading to modulation of the expression of RTEL1 and FUBP1 or modulation of RTEL1 and FUBP1 activity. The invention in particular relates to a combination of an inhibitor of RTEL1 and an inhibitor of FUBP1 for use in treating and/or preventing a disease, preferably a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of a combination of RTEL1 and FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. Also comprised in the present invention is a pharmaceutical composition, a kit and the use thereof in the treatment and/or prevention of a HBV infection.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
69.
OLIGONUCLEOTIDES CAPABLE OF INCREASING GLUCOCEREBROSIDASE EXPRESSION
The present invention relates to oligonucleotides that are complementary to aMTX1P1 mRNA and which lead to increased expression of glucocerebrosidase (GBA) in cells. The present invention further relates to conjugates, salts and pharmaceutical compositions thereof; and methods for treatment of diseases associated with reduced expression of GBA, including Parkinson's disease.
The present invention relates to antisense oligonucleotides that upregulate or restore the expression of GBA in cells; conjugates, salts and pharmaceutical compositions thereof; and their use in the treatment of Parkinson's and Gaucher's disease.
A method and system for predicting fibrosis development. Optical coherence tomography (OCT) image data may be received for a retina of a subject with neovascular age-related macular degeneration (nAMD). The OCT image data is processed using a model system comprising a machine learning model to generate a prediction output. A final output is generated based on the prediction output in which the final output indicates a risk of developing fibrosis in the retina.
Embodiments of the present disclosure relate to test result level based analysis. Some embodiments of the present disclosure provide a computer-implemented method. The method comprises obtaining a plurality of test result levels corresponding to a plurality of medical indicators of a patient, each test result level indicating that a quantitative test result of a corresponding medical indicator falls within one of a plurality of predetermined quantitative ranges; obtaining a plurality of reference test result levels corresponding to the plurality of medical indicators associated with a reference case, each reference test result level indicating that a quantitative reference test result of a corresponding medical indicator falls within one of the plurality of predetermined quantitative ranges; and determining a similarity between a medical condition of the patient and a reference medical condition associated with the reference case at least based on the plurality of test result levels and the plurality of reference test result levels. Through the solution, by means of test result level based analysis, it can protect the patient's privacy and obtain an accurate interpretation for the patient.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Tb0TTT. The present invention thus provides an automated analysis device with which it is possible to reduce the consumption of consumables that occurs when a reagent is registered, in comparison with a conventional device.
The present invention relates to antisense oligonucleotide splice modulators of actin-like 6B (ACTL6B). These antisense oligonucleotide splice modulators are complementary, such as fully complementary, to the ACTL6B precursor-mRNA, and are capable of increasing or restoring expression of ACTL6B in TDP-43 depleted cells, such as for use in conditions and medical indications where TDP-43 is functionally depleted.
The present invention provides for novel methods and compositions for nucleic acid sequence detection. Unique, identifying positively charged tags from oligonucleotide probes, bound to target nucleic acids, are produced during PCR by the 5`-nuclease activity of the polymerase. The identity of the targets can be determined by identifying the unique positively charged tags.
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention generally relates to antibodies that bind to CD3 and PLAP, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
78.
METHOD FOR PREPARING ANTIBODY-CONTAINING FORMULATION
Herein is reported a composition comprising a pair of a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises in the order a first part of a stem nucleic acid sequence, a cleavage site, a first stem loop nucleic acid sequences which 5'- and 3'-parts form a duplex, a first part of a catalytic core sequence, a second stem loop nucleic acid sequences which 5'- and 3'-parts form a duplex, a second part of the catalytic core sequence, and a second part of the stem nucleic acid sequence, which is complementary to the first part of the stem nucleic acid sequence and, thus, form a duplex therewith, wherein the second nucleic acid is complementary to at least a part of the first or the second part of the stem nucleic acid sequence, wherein binding of the second nucleic acid to the first nucleic acid results in a conformational change of the first nucleic acid, which is at least one of the dissociation of the first part of the first stem sequence from the second part of the stem sequence and the hybridization of one of the parts with the second nucleic acid, or the dissociation of loop I and loop II resulting in an inactivation of the catalytic 15 activity, or the association of loop I and loop II resulting in an activation of the catalytic activity.
A machine learning model for traversing a decision tree, the machine learning model trained from a structured data set including a first set of key-value pairs and subject-specific criteria using the key-value pairs. The first set of key-value pairs is transformed into a second set of key-value pairs, which are projected to a subject-specific point within a multi-dimensional space. The decision tree includes decision and leaf nodes. Each leaf node is connected to a root node via a leaf-node-specific trajectory. Each decision node corresponds to a criterion using a value in the second set of key-value pairs. For each leaf node, a leaf-node-specific point within the multi-dimensional space is determined using the leaf-node-specific trajectory, and a similarity score is determined using the leaf-node-specific and subject-specific points. A subset of the leaf nodes is identified using the scores. State or protocol information for each leaf node in the subset is retrieved.
The current invention is directed to a method for determining homodimeric avid-binding side-products of a bispecific antibody in a sample comprising the correctly assemble heterodimeric affine-binding bispecific antibody and the mis-assembled homodimeric avid-binding side-product of the bispecific antibody using surface plasmon resonance, wherein the correctly assembled heterodimeric affine-binding bispecific antibody comprises one or more binding site for a first antigen and one or more binding sites for a second antigen, wherein the mis-assembled homodimeric avid-binding side-product of the bispecific antibody comprises two or more binding sites to the first antigen but at least more than the correctly assembled bispecific antibody, wherein the correctly assembled bispecific antibody is a heterodimer and the mis-assembled bispecific antibody is a homodimer, wherein the presence of the homodimeric avid-binding side-product is determined if residual binding, i.e. an increased SPR signal, can be determined in the dissolution phase of the SPR analysis.
In a first aspect, the invention relates to a method for preparing a magnetic bead comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers, the method comprising steps (a) to (d), wherein at least one of steps (b), (c) and (d) is/are done under sonication, wherein sonication is done with an amplitude (peak-to-peak) in the range of from 50 to 250 µm. A second aspect of the invention is related to a magnetic bead comprising (i) at least one magnetic particle (M) and (ii) a silica coating, wherein the silica coat-ing comprises at least two silica layers; wherein the magnetic bead is stable against 7.5 M hydrochlorid acid and has a metal (cation) leaching rate in 7.5 M hydrochloric acid in the range of from 0.1 to 10%, wherein the metal (cation) leaching is deter-mined according to a complex formation of Fe2+ with bathophenanthroline according to Reference Example 8.2. In a third aspect, the invention relates to a functionalized magnetic bead comprising at least one, magnetic bead according to the second aspect, wherein an outer silica layer is functionalized with at least one group selected from the group consisting of amino group, azide group, alkyne group, carboxyl group, thiol group, epoxy group, aryl group and alkyl group. A fourth aspect of the invention is directed to a process for functionalizing a magnetic bead according to the second aspect comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers. A fifth aspect of the invention is related to a method for preparing magnetic Fe3O4 supra particles and a sixth aspect relates to the use of a magnetic bead according to the second aspect or of a functionalized according to the fourth aspect for immobilization of acid stable biocatalysts or for solid-phase organic synthesis using acid-stable linker.
H01F 1/33 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metallic particles having oxide skin
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
83.
COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES
The present invention relates to the combination therapy of a bispecific antibody which binds human TYRP1 and CD3 and a second TYRP1-specific antibody.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
85.
TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
86.
TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
87.
TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB
The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
88.
METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION
The present invention relates to a method for determining an analyte of interest by frequency detection and the use thereof, a modified nanopore, an analyzing system, a kit and the uses thereof.
The present invention generally relates to humanized antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to novel compounds having the general formula Ib wherein R1, R1b, R2, R3, and Z are as described herein, composition including the compounds and methods of using the compounds.
A method for controlling a laboratory system or device comprising at least one pipettor with a pressure sensor, at least one humidity sensor, at least one temperature sensor, and a control unit. The control unit receiving a humidity value from the humidity sensor and a temperature value from the temperature sensor, comparing the pair of humidity and temperature values with a threshold database connected to the control unit, the threshold database comprising, for different pairs of humidity and temperature values, instructions to activate or deactivate an anti droplet control system of the pipettor, determining if the anti droplet system of the pipettor has to be activated or deactivated, activating or deactivating said anti droplet system of the pipettor.
A laboratory system or device, comprising a reagent storage area (1) comprising at least two reagent drawers (2, 3) mounted slidably between an open position (O) and a closed position (C), each of the reagent drawers comprising receptacles for a plurality of reagent cartridges (RC1, RC2), and at least two locking mechanisms (4, 5) for respectively locking/unlocking the at least two reagent drawers (2, 3) when in the closed position (C), at least one robotic handler (6) and a control unit (7), wherein the reagent storage area (1) is subdivided in a loading zone (LZ), a storage zone (SZ) and a pipetting zone (PZ), and the reagent storage area (1) further comprises a handling zone (HZ).
Described herein is a variant pol6 polymerase having improved thermostability. The disclosed polymerases each contain one or more substitutions relative to SEQ ID NO: 1 selected from the group consisting of G12W/Y/F, K114W/F/I, L117L/F/P, N194F/W/V, M232W/G/R, G313E/Q/L, A451F/W/Y, K490W/F/Y, Q565Y/I/V, Q590P/V/Y, and D681G/N/H. Additionally, the present specification discloses substitutions that can reduce stuttering in such polymerases, the substitutions selected from the group consisting of N298L, L538R, P542A, I570H/T/W/R/N/G, N574L, E633W/F, S636F, E639K, and K655G.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
95.
NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
96.
COMPOSITIONS OF PROTEIN COMPLEXES AND METHODS OF USE THEREOF
Provided herein are protein complexes comprising a sensor domain and a therapeutic domain linked by a linker, and methods of use thereof. In aspects of the present disclosure, activity of the therapeutic domain comprises a dependence on sensor domain binding to target markers.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure pertains to a method for operating a laboratory automation system (1), the laboratory automation system (1) comprising a carrier (10) comprising a reception place (11) for receiving a sample container (12) configured to contain a sample to be analyzed by a laboratory device (13); a placement device (14) configured to pick and place the sample container (12); an imaging device (15); and a data processing device (16) comprising at least one processor (17) and a memory (18). The method comprises detecting an image of the reception place (11) by the imaging device (15); determining whether the reception place (11) is free for receiving the sample container (12) and the reception place (11) is configured to receive the sample container (12), by applying a machine learning algorithm for image analysis of the image of the reception place (11) in the data processing device (16); and placing the sample container (12) in the reception place (11) by the placement device (14) if the reception place (11) is determined as free and configured to receive the sample container (12). Further, a laboratory automation system (1) is disclosed.
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
A laboratory system or device comprising a control unit for controlling operation of the system or device, and a storage unit connected to the control unit and containing instruction for each assay type of the control type to be used when running said assay type, and, for each control type, an allocation rule for the control type. The control unit receiving at least one assay order comprising instructions to run at least one assay type on the system or device, determining for the at least one assay type comprised in the at least one assay order, the control type to be used, and the corresponding allocation rule for said control type, scheduling an assay run comprising instructions to include the determined control type based on the determined allocation rule, and controlling the system or device to perform the scheduled assay run.
A method for optimizing handlers operation in a laboratory system or device comprising at least two handlers movably arranged within the system or device in a shared area, and a control unit for controlling the operation of the at least two handlers comprising the following steps: defining for each of the handlers a task, receiving a first operation schedule, the operation schedule comprising a sequence of task to be performed by the handlers, starting operation of the handlers according to the received operation schedule, receiving a second operation schedule, creating an updated operation schedule, and continuing operation of the handlers according to the updated operation schedule.
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
The application relates to pyridazine derivatives of the general formula (Ib), to pharmaceutical compositions comprising the compounds and to their use in the treatment of diseases and conditions such as asthma, COPD, Parkinson's and Alzheimer's disease. The compounds act as inhibitors of NLRP3.
C07D 237/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
patents
